Michael J. Hansen

3.1k citations

46 papers · 1.8k indexed · 1 hit paper · h-index 15

Molecular Biology top 10%
Cell Biology top 2%
Cellular and Molecular Neuroscience top 5%
Immunology top 10%
Genetics top 10%

Co-authors: John G. Flanagan Neal G. Copeland Gaël McGill Heinz Arnheiter Timothy J. Hemesath Colin A. Hodgkinson David E. Fisher Eirı́kur Steingrı́msson
Topics: CAR-T cell therapy research (14 papers)Immunotherapy and Immune Responses (11 papers)Virus-based gene therapy research (8 papers)
Cited by: Cell Biology Developmental Neuroscience Cellular and Molecular Neuroscience
Journals: Nature Communications Neuron Genes & Development
Partner nations: United States Denmark Germany

In The Last Decade

Michael J. Hansen

44 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family.

1994 547 citations Michael J. Hansen et al. profile →

Peers

Countries citing papers authored by Michael J. Hansen

Since Specialization

Citations

This map shows the geographic impact of Michael J. Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Hansen more than expected).

Fields of papers citing papers by Michael J. Hansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Hansen. The network helps show where Michael J. Hansen may publish in the future.

Co-authorship network of co-authors of Michael J. Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Hansen. A scholar is included among the top collaborators of Michael J. Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Hansen. Michael J. Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens 2025 ·Journal for ImmunoTherapy of Cancer ·James W. Jenkins,(unknown),(unknown),Michael J. Hansen,Virginia P. Van Keulen,(unknown),(unknown),(unknown),(unknown),(unknown),Kevin D. Pavelko,Sara J. Felts,Aaron J. Johnson,Larry R. Pease	2
2	Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression 2023 ·Cancer Immunology Research ·(unknown),Katayoun Ayasoufi,(unknown),(unknown),Courtney S. Malo,Benjamin Himes,Cori E. Fain,Emma N. Goddery,(unknown),(unknown),Michael J. Hansen,Ian F. Parney,Chensu Wang,Kelly D. Moynihan,Darrell J. Irvine,K. Dane Wittrup,(unknown),Richard G. Vile,Aaron J. Johnson	1
3	Comparison of replicating and nonreplicating vaccines against SARS-CoV-2 2022 ·Science Advances ·(unknown),Shane Massey,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Michael J. Hansen,Courtney L. Erskine,Virginia P. Van Keulen,Aleksandra Drelich,(unknown),Madiha Fida,Gina A. Suh,Tobias Peikert,Matthew S. Block,Chien‐Te K. Tseng,(unknown),Michael A. Barry	9
4	Liver mesenchymal stem cells are superior inhibitors of NK cell functions through differences in their secretome compared to other mesenchymal stem cells 2022 ·Frontiers in Immunology ·(unknown),(unknown),(unknown),Walter D. Park,Michael J. Hansen,Surendra Dasari,Mark D. Stegall,Timuçin Taner	10
5	Flow Assisted Mutation Enrichment (FAME): A highly efficacious and efficient method to enrich Double Knockouts (DKO) after gene editing 2021 ·PLoS ONE ·Michael J. Hansen,(unknown),(unknown),David A. Largaespada,(unknown)	1
6	Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L 2021 ·Human Gene Therapy ·(unknown),Michael J. Hansen,(unknown),(unknown),(unknown),Michael A. Barry	7
7	Conditional Silencing of H-2Db Class I Molecule Expression Modulates the Protective and Pathogenic Kinetics of Virus-Antigen–Specific CD8 T Cell Responses during Theiler's Virus Infection 2020 ·The Journal of Immunology ·(unknown),(unknown),Courtney S. Malo,Katayoun Ayasoufi,Cori E. Fain,Roman H. Khadka,Emma N. Goddery,(unknown),Megan L. Settell,Michael J. Hansen,Fang Jin,Kevin D. Pavelko,Larry R. Pease,Aaron J. Johnson	7
8	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma 2020 ·Biology of Blood and Marrow Transplantation ·Reona Sakemura,Michelle J. Cox,Mehrdad Hefazi,Michael J. Hansen,Roman H. Khadka,Claudia Manriquez Roman,Kendall J. Schick,Erin E. Tapper,Paulina Horvei,Michael W. Ruff,Denise K. Walters,Sameer A. Parikh,Neil E. Kay,Saad S. Kenderian	1
9	Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma 2018 ·Frontiers in Oncology ·Courtney S. Malo,Roman H. Khadka,Katayoun Ayasoufi,Fang Jin,(unknown),Michael J. Hansen,Raymond Iezzi,Kevin D. Pavelko,Aaron J. Johnson	37
10	Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 + T cell responses 2018 ·Nature Communications ·Courtney S. Malo,Matthew A. Huggins,Emma N. Goddery,(unknown),(unknown),Fang Jin,Michael J. Hansen,Larry R. Pease,Kevin D. Pavelko,Aaron J. Johnson	34
11	Folate receptor expression on murine and human adipose tissue macrophages 2015 ·Inflammation Research ·Michael J. Hansen,(unknown),Philip S. Low	6
12	Nonequivalence of Classical MHC Class I Loci in Ability to Direct Effective Antiviral Immunity 2012 ·PLoS Pathogens ·Kevin D. Pavelko,Yanice Mendez-Fernandez,Michael P. Bell,Michael J. Hansen,Aaron J. Johnson,Chella S. David,Moses Rodriguez,Larry R. Pease	6
13	Cocal-pseudotyped Lentiviral Vectors Resist Inactivation by Human Serum and Efficiently Transduce Primate Hematopoietic Repopulating Cells 2009 ·Molecular Therapy ·Grant D. Trobridge,R. Alex Wu,Michael J. Hansen,Christina Ironside,Korashon L. Watts,Philip Olsen,Brian C. Beard,Hans‐Peter Kiem	51
14	Semaphorin 5A Is a Bifunctional Axon Guidance Cue Regulated by Heparan and Chondroitin Sulfate Proteoglycans 2004 ·Neuron ·David B. Kantor,Onanong Chivatakarn,Katherine L. Thompson-Peer,Stephen F. Oster,Masaru Inatani,Michael J. Hansen,John G. Flanagan,Yu Yamaguchi,David W. Sretavan,Roman J. Giger,Alex L. Kolodkin	310
15	MHC Class I Gene Conversion Mutations Alter the CD8 T Cell Repertoire 2003 ·The Journal of Immunology ·Matthew S. Block,Michael J. Hansen,Virginia P. Van Keulen,Larry R. Pease	8
16	Enhanced binding of low‐affinity antibodies interacting simultaneously with targeted cell surface molecules and Fc receptor 2002 ·Tissue Antigens ·Yanice Mendez-Fernandez,(unknown),Matthew S. Block,Aaron J. Johnson,Scott Kuhns,(unknown),Michael J. Hansen,Larry R. Pease	2
17	Retroviral Vector-Modified Bone Marrow Stromal Cells Secrete Biologically Active Factor IX In Vitro and Transiently Deliver Therapeutic Levels of Human Factor IX to the Plasma of Dogs after Reinfusion 1998 ·Human Gene Therapy ·Van Cherington,Gisela G. Chiang,(unknown),(unknown),Theofanis Galanopoulos,(unknown),(unknown),Michael J. Hansen,(unknown),Peter H. Levine,Joel S. Greenberger,David R. Hurwitz	33
18	Enhanced growth of canine bone marrow stromal cell cultures in the presence of acidic fibroblast growth factor and heparin 1997 ·In Vitro Cellular & Developmental Biology - Animal ·Shahin Emami,(unknown),Van Cherington,Gisela G. Chiang,Michael Kirchgesser,(unknown),Michael J. Hansen,Peter H. Levine,Joel S. Greenberger,David R. Hurwitz	6
19	The ompA 5′ untranslated region impedes a major pathway for mRNA degradation in Escherichia coli 1994 ·Molecular Microbiology ·Michael J. Hansen,(unknown),Marlena S. Fejzo,(unknown)	70
20	Interviewing, motivation, and clinical judgment 1975 ·Academic Medicine ·(unknown),John Francis McDermott,William Haning,Michael J. Hansen	1

About Michael J. Hansen

Michael J. Hansen is a scholar working on Immunology, Genetics and Oncology, having authored 46 papers that have together received 1.8k indexed citations. Recurring topics across this work include CAR-T cell therapy research (14 papers), Immunotherapy and Immune Responses (11 papers) and Virus-based gene therapy research (8 papers). The work is most often cited by research in Cell Biology (535 citations), Developmental Neuroscience (130 citations) and Cellular and Molecular Neuroscience (396 citations). Michael J. Hansen has collaborated with scholars based in United States, Denmark and Germany. Frequent co-authors include John G. Flanagan, Neal G. Copeland, Gaël McGill, Heinz Arnheiter, Timothy J. Hemesath, Colin A. Hodgkinson, David E. Fisher, Eirı́kur Steingrı́msson, N.A. Jenkins and Gerard E. Dallal. Their work appears in journals such as Nature Communications, Neuron and Genes & Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact